Clinical Trials

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of...

Admin - May 17, 2021

Clinical Trials

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that...

Admin - May 17, 2021

Clinical Trials

Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform

MENLO PARK, Calif.--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the first-ever...

Admin - May 13, 2021

Clinical Trials

Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced...

Admin - May 13, 2021

Clinical Trials

Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3...

Admin - May 13, 2021

Clinical Trials

Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024, a Novel Precision Medicine Product Candidate for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced...

Admin - May 13, 2021

12 3...62 Page 1 of 62

Eurofins at the Forefront of Innovation with New Developments for Detection and Identification of Emerging COVID-19 Variants of Concern

Industry News May 17, 2021

GenSight Biologics Appoints Françoise de Craecker to its Board of Directors

Look Who’s On the Move! May 17, 2021

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

Editor´s Pick May 17, 2021

PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery

Industry News May 17, 2021

Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor – Gamma Delta T-cell...

Regulatory Affairs May 17, 2021

Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

Industry News May 17, 2021

Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board

Look Who’s On the Move! May 17, 2021

MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors

Industry News May 17, 2021

Henry Schein Elects Reed V. Tuckson, M.D., FACP to Board of Directors

Look Who’s On the Move! May 17, 2021

Neurodon Announces Initiation of Investigational New Drug (IND)-Enabling Studies for NDC-0009, a Novel Small Molecule for the Treatment of Type 1 Diabetes (T1D)

Industry News May 17, 2021

Returning to In-Person Engagement Is a High Priority for Most Biopharma Chief Commercial Officers, but Returning Sales Reps to In-Person Engagement Is a Work-in-Progress

Industry News May 17, 2021

Clinical Trials

Recent Articles

Eurofins at the Forefront of Innovation with New Developments for Detection and Identification of Emerging COVID-19 Variants of Concern

GenSight Biologics Appoints Françoise de Craecker to its Board of Directors

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery

AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer

Centessa Pharmaceuticals Announces Expansion of Management Team and Board of Directors

HempFusion Signs Definitive Agreement to Acquire Pioneering CBD Brand Apothecanna

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor – Gamma Delta T-cell...

Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab

Caribou Biosciences Announces Appointment of Katy Rezvani, M.D., Ph.D. and Christopher Sturgeon, Ph.D. to its Scientific Advisory Board

MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors

Henry Schein Elects Reed V. Tuckson, M.D., FACP to Board of Directors

Neurodon Announces Initiation of Investigational New Drug (IND)-Enabling Studies for NDC-0009, a Novel Small Molecule for the Treatment of Type 1 Diabetes (T1D)

Returning to In-Person Engagement Is a High Priority for Most Biopharma Chief Commercial Officers, but Returning Sales Reps to In-Person Engagement Is a Work-in-Progress